Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mutant keratin intermediate filament proteins are altered forms of keratin proteins, a major component of the cytoskeleton in epithelial cells. These mutations disrupt filament assembly or stability, leading to weakened cellular structures and various diseases such as epidermolysis bullosa simplex. Mutations can affect dimerization, post-translational modification sites (e.g., phosphorylation), and interactions with regulatory proteins, altering network dynamics and mechanosensitivity.
Not applicable - focus is on the mutant protein itself, not drugs targeting it directly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mutant Keratin Intermediate Filament Proteins (Mutant Keratin IF).